London, UK, 11 Dec 2025, ZEX PR WIRE, Stelios Tzellos, Ph.D., continues to be recognized within the pharmaceutical industry for his contributions to oncology market analysis and strategic forecasting. With a formal background in molecular biology and biochemistry from Imperial College London and multiple years of applied experience in healthcare analytics, Tzellos’ work has informed commercial planning and strategic evaluation across multiple therapeutic areas, particularly within oncology.

Dr. Tzellos earned his Bachelor’s and Master’s degrees in Biochemistry and went on to complete a Ph.D. in Molecular Biology, all from Imperial College London. His doctoral research focused on Epstein-Barr virus (EBV) gene regulation, specifically the functional differences between EBNA-2 type 1 and type 2 proteins. His findings, published in peer-reviewed journals, helped expand understanding of how EBV regulates the expression of cellular genes like CXCR7 and viral genes such as LMP-1.

His academic contributions during his Ph.D. program include co-authorship of studies examining how specific amino acid changes in EBNA-2 affect the regulation of growth-promoting genes. One study, published in the Journal of General Virology in 2014, was titled “EBV EBNA-2 type 1 and type 2 proteins induce expression of the cellular CXCR7 and EBI2 genes through a mechanism involving a common motif in their transactivation domains.” Another article, where he was the first author, expanded on the same theme of differential gene activation.

In 2014, while working as an Oncology and Haematology Analyst for GlobalData, Dr. Tzellos was quoted in a widely circulated industry report forecasting trends in Hodgkin’s lymphoma treatment. That report examined the expanding use of Adcetris and the emergence of premium-priced therapies targeting relapsed or refractory (R/R) populations. In the report, Dr. Tzellos stated:

“Adcetris currently accounts for 77.6% of the total market and is predicted to make up 82.4% of sales by the end of the forecast period. Premium-priced pipeline therapies that target the R/R Hodgkin’s lymphoma population will find it easier to penetrate the market, as Adcetris has already opened the door for expensive therapeutics in this setting.”

The analysis helped contextualize the broader adoption of targeted agents and immunotherapies in hematologic malignancies and emphasized the commercial implications of label expansions and earlier-line use. Dr. Tzellos’ quote has since been referenced by healthcare publications analyzing pricing strategy and market evolution in oncology.

After his tenure at GlobalData, Dr. Tzellos joined IQVIA, where he continued to work in pharmaceutical analytics. He later moved into a commercial-facing analytics position at AstraZeneca in the UK. Across these roles, his focus has remained in strategic insight, analytics, and pharmaceutical development, particularly in oncology.

Dr. Tzellos’ professional experience intersects research, forecasting, and healthcare consulting. His work contributes to decision-making processes related to product planning, commercialization strategy, and global market evaluation. While he has not authored publicly available white papers under AstraZeneca or IQVIA, he continues to post periodically on Medium and LinkedIn about trends in pharmaceutical strategy and oncology analytics.

He resides in the United Kingdom with his wife and their two children. Outside of work, he has a range of personal interests including football, basketball, Formula 1, attending live music events, and engaging in DIY home projects.

Dr. Tzellos’ career exemplifies a transition from academic molecular biology research to high-impact pharmaceutical strategy and analytics. His ongoing work remains grounded in scientific evidence while addressing real-world commercial challenges in oncology drug development.